Investigational drug · Phase 3
Canvuparatide
Also called: MBX 2109
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypoparathyroidism.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Canvuparatide"
First trial start
2024
Aug 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Canvuparatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypoparathyroidism
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Canvuparatide" as an intervention, largest first.
- A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With HypoparathyroidismPivotal-lookingRecruiting
MBX BiosciencesIndustry
NCT07699471 · 160 participants (planned) · Start Aug 26, 2026 · Primary completion Jan 2028
Drug: Canvuparatide · For: Hypoparathyroidism
Sites: Sacramento, California; Aurora, Colorado; Englewood, Colorado · 28 sites in all
MBX BiosciencesIndustry
NCT06465108 · 64 participants · Start Aug 8, 2024 · Primary completion May 23, 2025
Drug: MBX 2109 · For: Hypoparathyroidism
Sites: Sacramento, California; Jacksonville, Florida; Miami, Florida · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Hypoparathyroidism: translating science from the laboratory to the clinic.
Brandi ML, AbuAlrob H, Chang W, et al. · Lancet Diabetes Endocrinol 2026
- Hypoparathyroidism: a review of clinical trials and recent approvals.
De Leo S, Maffei Faccioli F, Succi M, et al. · Expert Opin Pharmacother 2026
- Discovery and characterization of canvuparatide, a once-weekly parathyroid hormone analog for the treatment of hypoparathyroidism.
Zhang F, Perez-Tilve D, Allen MR, et al. · Mol Metab 2026
- Exploring the Potential of Weekly Parathyroid Hormone Therapy for Hypoparathyroidism.
Tabacco G · J Clin Endocrinol Metab 2025
- Correction to: "MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial".
· J Clin Endocrinol Metab 2025
- MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial.
Carney P, Cutler GB, Schneider K, et al. · J Clin Endocrinol Metab 2025
Also in development for Hypoparathyroidism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.